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Background: Ameloblastoma is a common locally invasive but slow-growing neoplasm of the jaws with an odontogenic 
origin. Association between BRAF V600E mutation and clinicopathologic features and behavior of ameloblastoma 
remains controversial. This study aimed to evaluate BRAF V600E gene mutation and expression of its related proteins 
with clinicopathologic parameters in conventional ameloblastoma.
Material and Methods: 50 Formalin-fixed paraffin-embedded blocks were included in this study. Immunohistochem-
istry was done using rabbit monoclonal BRAF V600E mutation-specific antibody VE1. Quantitative real-time poly-
merase chain reaction assay was used for evaluating of BRAF V600E mutation.
Results: Expression of BRAF V600E antibody was Positive in 42 out of 50 cases (84%). 46 (92%) out of 50 specimens 
showed BRAF V600E mutation. There were 13 cases of recurrence (26%). 3 out of 4 cases with negative mutations did 
not show recurrence.
Conclusions: We report the highest frequency (92%) of BRAF V600E mutation in ameloblastomas in the Iranian popu-
lation. Although there was not a significant association between BRAF V600E-positive immunoexpression and recur-
rence and clinicopathologic parameters, its high frequency could emphasize its role as a therapeutic marker in the future.
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Introduction
Ameloblastoma is a common locally invasive but slow-
growing neoplasm of the jaws with odontogenic origin 
(1). Although ameloblastoma does not have metastatic 
potential, facial deformity, significant morbidity and 
also recurrence in more conservative approaches, oc-
cur due to surgical treatment (2). Recent molecular find-
ings tend to result in novel insights into discovering the 
pathogenesis, mechanisms and treatment of ameloblas-
toma. Mutation in BRAF gene-valine (V) to glutamic 
acid (E) substitution at codon 600 is a common muta-
tion in ameloblastoma. Heikinheimo et al. reported this 
mutation in 74% of the analyzed conventional amelo-
blastoma samples (3). However, the association between 
BRAF V600E mutation and clinicopathologic features 
and behavior of ameloblastoma remains controversial 
(4,5). Here, we analyzed the mutation of BRAF V600E 
by qPCR and also the expression of BRAF V600E pro-
tein by immunohistochemistry. We also studied the cor-
relation between BRAF V600E mutation and clinico-
pathologic parameters of conventional ameloblastoma.
Material and Methods 
- Samples
We included 50 Formalin-fixed paraffin-embedded 
(FFPE) blocks obtained from the files of the Oral and 
Maxillofacial Pathology Department of Tehran Univer-
sity of Medical Sciences, and Shariati Hospital in this 
study. All of the cases were diagnosed as Conventional 
Ameloblastoma, according to the International Histo-
logical Classification of Odontogenic Tumors guide-
lines published by the WHO (6). Two oral pathologists 
reviewed all the slides and confirmed the diagnosis. We 
obtained the demographic data of each sample (Table 1).
- BRAF V600E immunohistochemistry
Immunohistochemistry was done on 3-µm paraffin-
embedded sections according to standard procedures. 
Tris/EDTA buffer solution (pH 9) (Carpinteria, Dako, 
CA, USA) was used to antigen retrieval following in 
microwave in boiling point for 15min. The slides were 
put in room temperature for 15min to decrease the tem-
perature. The primary antibody incubation was per-
formed for 1h and 30min at room temperature using 
Rabbit monoclonal BRAF V600E mutation-specific an-
tibody VE1 (Recombinant RabMAb, Anti-B Raf anti-
body [EP152Y], ABCAM, Cambridge, Code# ab33899) 
with a dilution ratio of 1:150. Malignant melanoma with 
known presence of BRAF V600E mutation was used as 
positive controls. The omission of the primary antibody 
and using phosphate-buffered saline was done as the 
negative control.
- Scoring of Immunohistochemistry
Two experienced oral pathologists blindly evaluated the 
quantity and expression of BRAF V600E mutation for 
each stained section and used a composite semi-quan-
titative IHC-scoring scale, including intensity (0-3+) 
combined with staining percent of neoplastic cells (0%-
100%) (7). We determined cytoplasmic brown staining 
in tumoral cells as positive staining and single nuclear 
staining, faint diffuse staining or staining of single in-
terspersed stromal inflammatory cells as negative. We 
Determined positive BRAF V600E-staining intensity as 
follows: the absence of staining (0); mild staining appre-
ciable only in 400× magnification (1); moderate staining 
apparent in 100× magnification (2); and intense staining 
apparent in 40× magnification (3). We determined BRAF 
V600E immunoreactivity by stringent scoring criteria 
(intensity of ≥2+ and percent of 1˃0%) as described (7,8).
- Detection of BRAF V600E mutation by Quantitative 
Real Time-PCR
Evaluation of BRAF V600E mutation was performed 
using quantitative real-time polymerase chain reaction 
(PCR) assay. DNA was extracted from FFPE tissue sam-
ples (10-μm section per sample) using the DNA extrac-
tion kit (Yekta Tajhiz, Iran and Taiwan) according to the 
manufacturer’s protocols. The DNA was quantified by 
using the NanoDrop spectrophotometer (ThermoFisher, 
OneC). Real-time PCR assay designed to detect the 
presence of the BRAF mutation (V600E) in FFPE am-
eloblastoma specimens by using ANA Gene PCR kit, 
Iran, Karaj. Validated protocols for BRAF V600 mu-
tation detection with a limit of detection (LOD) of 1% 
variant allele frequency were adopted from previously 
published literature. The process has been checked by 
using BRAF internal control. BRAF positive malignant 
melanoma was used as the positive control. Also, one 
NTC (no template control) has been used for each run 
as the negative control.
- Statistical analysis
We used the Statistical software IBM SPSS statistics 
23.0 (IBM Corporation, Armonk, NY, USA) for the 
analysis of the data. We used Mann-Whitney test to find 
a correlation between the parameters and considered 
the level of P-value ≤ 0.05 as statistically significant.
Results
- Study samples
Our results showed that 29 out of 50 cases were male 
(58%), with a mean age of 42 years and 21 cases were 
female (42%) with a mean age of 46 years. Forty-four 
cases were in the mandible (88%), 5 cases were in the 
maxilla (10%), and one case showed involvement of both 
jaws (2%). The involvement of the mandible was rath-
er equally on the right (28 cases, 56%) and the left (21 
cases, 42%) side. One case demonstrated involvement 
bilaterally (2%). The follow-up duration was between 1 
to 17 (average 6) years. Majority of the cases (37,74%) 
did not show recurrence compared to recurrent cases (n 
= 13, 26%). Histologically, in most of the cases follicu-
lar pattern was predominant over the other patterns (46 
cases, 92%), also 2 cases (4%) showed mainly plexiform 
pattern, 1 case (1%) showed mainly basal cell type and 
one case (2%) showed both follicular and plexiform pat-
tern equally. All the results are present in Table 1.
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Sample 







1 Man L 32 M Follicular Pos 3 90 Pos No Rec
2 Man R & L 74 M Follicular Pos 1 70 F Neg Rec
3 Man L 28 F Follicular Pos 3 70 Pos Rec
4 Man R 36 M Follicular Pos 3 90 Pos No Rec
5 Man R 34 F Follicular Neg 3 80 F Pos No Rec
6 Man L 30 M Follicular Pos 0 0 F Neg No Rec
7 Man L 17 F Basalloid Pos 3 5 F Neg No Rec
8 Man R 18 M Follicular Pos 3 100 Pos No Rec
9 Man L 88 M Follicular Pos 2 50 Pos No Rec
10 Man R 38 F Follicular Pos 3 80 Pos No Rec
11 Man R 25 M Follicular Pos 3 50 Pos Rec
12 Man L 45 M Follicular Pos 3 100 Pos No Rec
13 Man R 48 M Plexiform Pos 3 5 F Neg No Rec
14 Man R 48 F Follicular & Plexiform Pos 3 90 Pos No Rec
15 Man R 37 M Follicular Pos 3 70 Pos No Rec
16 Man R 45 M Plexiform Pos 3 100 Pos No Rec
17 Man L 20 F Follicular Pos 3 100 Pos No Rec
18 Man R 34 F Follicular Pos 3 45 Pos Rec
19 Man R 22 M Follicular Pos 2 5 F Neg No Rec
20 Man R 63 F Follicular Pos 3 25 Pos No Rec
21 Man L 14 M Follicular Pos 2 70 Pos No Rec
22 Man R 31 F Follicular Pos 3 90 Pos No Rec
23 Man R 30 M Follicular Pos 3 70 Pos No Rec
24 Man R 45 M Follicular Pos 2 70 Pos Rec
25 Man R 43 M Follicular Pos 2 75 Pos No Rec
26 Man R 56 F Follicular Pos 2 30 Pos Rec
27 Man L 37 M Follicular Pos 2 60 Pos No Rec
28 Man L 58 F Follicular Pos 2 80 Pos No Rec
29 Man R 51 F Follicular Pos 3 70 Pos No Rec
30 Max R 61 M Follicular Pos 3 90 Pos No Rec
31 Man R 65 M Follicular Pos 2 80 Pos No Rec
32 Man L 71 M Follicular Pos 3 95 Pos No Rec
33 Man R 38 F Follicular Pos 3 50 Pos No Rec
34 Man L 43 M Follicular Pos 0 0 F Neg No Rec
35 Man L 53 F Follicular Pos 2 60 Pos No Rec
36 Man L 41 M Follicular Pos 2 50 Pos No Rec
37 Man L 53 F Follicular Pos 3 90 Pos No Rec
38 Man L 38 F Follicular Pos 3 70 Pos No Rec
39 Man L 50 M Follicular Pos 0 0 F Neg No Rec
40 Man R 40 F Follicular Neg 0 0 Neg No Rec
41 Man R 34 F Follicular Pos 1 80 F Neg No Rec
42 Max R 53 F Follicular Pos 3 10 Pos Rec
43 Max L 25 F Follicular Pos 2 10 Pos Rec
44 Man R 50 M Follicular Pos 2 60 Pos No Rec
45 Max & Man L 51 M Follicular Pos 2 50 Pos Rec
46 Man L 43 M Follicular Neg 3 80 F Pos Rec
47 Man R 68 M Follicular Neg 1 5 Neg No Rec
48 Man L 14 M Follicular Pos 3 80 Pos Rec
49 Max R 50 F Follicular Pos 1 10 F Neg Rec
50 Max R 52 M Follicular Pos 3 80 Pos Rec
Man: mandible, Max: maxilla, R: right side, L: left side, M: male, F: female, Neg: negative; Pos: positive, Rec: recurrence.
Table 1: Clinical details and BRAF V600E immunohistochemical status of ameloblastoma cases.
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Discussion
Ameloblastoma is a benign slow-growing odontogenic 
neoplasm of the jaws which accounts for 10% of all 
maxillary and mandibular neoplasms (9,10).
The high recurrence rate of ameloblastoma after con-
servative therapy (55-90%) is a noticeable issue (9). On 
the other hand, functional and psychological impair-
ments and aesthetic deformities after radical surgical 
treatment, especially in large ameloblastomas, are seri-
ous issues (9). It seems that a novel treatment approach 
may be helpful to avoid extensive surgical treatments. 
In 2014, several studies reported the mutation of BRAF 
V 600E in 40-80% of ameloblastomas (2,4,11,12). In 
the present study, we reported the highest frequency of 
BRAF V 600E (92%), which is reported in the literature 
in the Iranian population mutation ameloblastomas.
Different authors reported alterations in BRAF muta-
tion frequency for ameloblastoma. Sweeney et al. re-
ported the mutation of BRAF V 600E in 46% of their 
cases (12). Brown et al. and Kurppa et al. found BRAF 
V600E mutation in 62% and 63% of their cases, respec-
tively (2,4). In 2015, one study reported by Diniz de-
scribed the BRAF mutation in 82 % of their samples (11).
Gultekin et al. in a recent study reported the BRAF V 
600E mutation in 60% of patients which was the most 
prevalent mutation (13). To the best of our knowledge, 
we report the highest frequency of BRAF V600E muta-
tion in ameloblastomas which is reported yet as 82% by 
Diniz (11). There is one previous study about the BRAF 
V600E mutation in Iranian patients with ameloblasto-
ma. Soltani et al. reported this mutation in 63% (12 of 
19) of cases in a cohort study (14).
Although some papers described the correlation of 
BRAF mutation and clinicopathologic features such as 
age or anatomical location (4,13,15,16), despite the high 
frequency of the mutation, we did not find any signifi-
cant association between clinical and histopathological 
findings and BRAF V600E mutation.
The correlation between BRAF V600E mutation and 
aggressiveness of ameloblastoma remains conflicting. 
- IHC results and molecular analysis 
According to stringent scoring criteria (intensity of 
≥2+ and percent of ˃10%), we observed positive BRAF 
V600E immunostaining in 42 samples (84%) (Fig 1). 8 
cases (16%) showed negative BRAFV600E immunos-
taining. In cases with recurrence, 11 cases showed posi-
tive immunostaining, and 2 cases showed negative im-
munostaining. There was no correlation between BRAF 
V600E immunostaining and clinicopathologic criteria 
(P-value higher than 0.05).
Fig. 1: Immunohistochemistry view. a) Moderate immunostain-
ing of tumoral cells (Plexiform pattern ×100 magnification) b) 
Severe immunostaining of tumoral cells (Follicular pattern ×100 
magnification).
The BRAF V600E mutation was detected in 46 cases 
(92%) out of 50 samples. Four negative BRAF V600E 
mutations were in the mandible and demonstrated a 
mainly follicular histopathologic pattern. Clinical char-
acteristics and molecular analysis of the four cases with 
negative BRAF V600E mutation are present in Table 2. 
In cases with recurrence, 12 of them showed a positive 
molecular result, and 1 case showed a negative molecular 
result. There was no correlation between BRAF V600E 
mutation and clinicopathologic criteria (P-value high-
er than 0.05). Recurrence was significantly associated 
with the occurrence of ameloblastoma in the maxilla.
Location Man Man Man Man
Location R R L R
Age 34 40 43 68











PCR Neg Neg Neg Neg
IHC Intensity 3 0 3 1
IHC Percent 80 0 80 5
Concordance F Pos Neg F Pos Neg
Recurrence No Rec No Rec Rec No Rec
Man: mandible, Max: maxilla, R: right side, L: left side, M: male, F: 
female, Neg: negative; Pos: positive, Rec: recurrence.
Table 2: Clinical data of the four ameloblastoma cases with negative 
BRAF V600E mutation results.
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Some studies described higher disease-free survival in 
ameloblastomas with BRAF V600E mutation (4,12). On 
the other hand, Fregnani et al. reported poor disease-
free survival and more aggressive tumor for positive 
BRAF V 600E mutation (5). Some studies showed a 
lower risk of recurrence in patients with BRAF V 600E 
mutation (13,16), while Shirsat et al. described a sig-
nificant association of positive immune-expression of 
BRAF V600E with recurrence (17). In this study, we did 
not find any association between BRAF V600E muta-
tion and recurrence. Although we found a higher recur-
rence rate in maxillary tumors, this higher recurrence 
rate may also be due to treatment limitations based on 
limited access to safe margins.
There are some in vitro studies that have described the 
sensitivity of BRAF inhibitors in ameloblastoma cells 
with BRAF V600E mutation (4,12). Besides, three cases 
with BRAF V600E mutation showed a successful re-
sponse to BRAF inhibitors (18-20). It seems that BRAF 
inhibitors can have clinical benefits and responses in re-
current and metastatic ameloblastomas and use as neo-
adjuvant and/or targeted adjuvant therapy to improve 
the treatment outcome, especially in locally advanced 
ameloblastomas (21,22). Although new molecular 
medicine demonstrates personalized targeted therapy 
for ameloblastoma, it seems that based on lack of large 
scale clinical trials, evaluation of the wide clinical ap-
plication of BRAF inhibitors has a long way. 
According to significant evidence of activating MAPK 
pathway in the pathogenesis of ameloblastoma (4) and 
since BRAF is the most prominent activator of this 
pathway (23,24), high frequency of BRAF mutation in 
ameloblastoma in Iranian population demonstrate the 
possibility of MAPK pathway activation in the patho-
genesis of this aggressive benign tumor.
Our results did not show a correlation between BRAF 
V600E immunoexpression and molecular analysis of 
this mutation. These findings are not consistent with 
the previous studies of readily detectable of BRAF 
V600E expression by immunohistochemistry evalua-
tion and correlation with mutation status in ameloblas-
toma (25-27).
To our surprise, we detected the highest frequency 
of BRAF V600E mutation in our study. It seems that 
geographic and ethnic criteria may be possible reasons 
for these results and future multicentric studies are 
required for further evaluation and analysis of BRAF 
V600E mutation status and its role as a predictor or 
therapeutic marker.
We want to highlight the significance of our study that 
has a large sample size and acceptable follow-up du-
ration in which both mandibular and maxillary amelo-
blastomas are included.
Conclusions
The present study reported the highest frequency of 
BRAF V600E mutation in ameloblastomas (92%) com-
pared with the previous studies till now. We highlighted 
the correlation between BRAF V600E immunoexpres-
sion and molecular analysis of this mutation in amelo-
blastomas. Since the dependency of clinicopathologic 
data and BRAF V600E mutation in ameloblastomas re-
mains questionable and conflicting, further studies are 
required in future to explain the real relationship of this 
mutation with the aggressiveness of ameloblastoma.
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